Statistical Considerations Clause Samples

Statistical Considerations. Standard statistical methods will be employed to determine primary and secondary efficacy and safety outcomes. Depending on the final study design, BioForm may consult with appropriate statistical authorities to both determine the effectiveness of the surgery and accurately assess a change over time using a 95% confidence interval. BioForm expects to enroll up to [****] patients at up to [****] investigator sites. Standard screening and evaluation criteria may be employed to identify the appropriate patient population. [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Statistical Considerations. Statistical analysis will focus on longer term safety, fracture incidence, including vertebral fracture and BMD change following six months of standard-of-care osteoporosis treatment in subjects who have previously received 18 months of blinded treatment with BA058 Injection 80 µg/Placebo. The analyses will be performed based on the treatment arm they were randomized to in the BA058-05-003 study. The analyses performed on data collected at Month 12 and Month 24 will be descriptive in nature and will be summarized descriptively with number, percentage (for categorical variables), mean, standard deviation, median, minimum and maximum (for continuous variables). The analyses performed at six months will be used as a follow-up to the 18 month fracture endpoint for Study BA058-05-003. At this time-point, subjects will be analyzed based upon the randomization assignment in the BA058-05-003 study.

Statistical Considerations. The statistical analyses will assess longer term safety, fracture incidence (including vertebral and non-vertebral fracture), and BMD change following treatment with alendronate for six months after the completion of a subject’s participation of 18 months in study BA058-05-003. The efficacy and safety analyses performed at six months will be used as a follow-up to the 18 month fracture endpoint for Study BA058-05-003. At this time-point, subjects will be analyzed based on the randomization assignment in the BA058-05-003 study.

Statistical Considerations. This is a two-center study, with equal numbers of patients treated at each site. All patients receive CaPVax injections and act as their own controls. The treatment plan is presented in Section 5.0. 37

Statistical Considerations. Describe the statistical analyses that support the study design. This section should include: o The number of subjects expected to enter the study. o A statement about the statistical power of the study to test the major hypothesis. o A summary of the plans for data analysis. The number of subjects expected to be enrolled in the study will be 300 hundred people. We hope the study will generate significant power, however secondary to unknown standard deviation and the level of significance we can't predicate the power. After the study we will calculate the p-value and power for it's ability to map perforators and it's ability to monitor flap viability.

Statistical Considerations. Sample Size

Statistical Considerations. The study plans to enroll approximately 50-200 individuals that will be diagnosed with Obstructive Sleep Apnea (OSA) and begin PAP therapy, as part of the study procedures. It is recognized that the sample size achieved in this baseline study will likely be insufficient for statistical hypothesis testing, but it will still be useful for establishing a baseline understanding of the performance of the VSA program. The primary endpoints of interest are five timelines relating to the patient diagnostic and treatment journey: ● Time (number of days) from when participant is told they may have OSA to OSA diagnosis ○ Time (number of days) from when participant is told they may have OSA to when they receive HST prescription ○ Time (number of days) from when participant receives HST prescription to OSA diagnosis ● Time (number of days) from OSA diagnosis to PAP therapy initiation ● Time (number of days) from therapy initiation to when 90-day compliance threshold is achieved Each of these will be reported as a point estimate accompanied by a confidence interval. These will be calculated from the average and standard deviation of these timeframes across all participants. ●

Statistical Considerations. This is a two-center study, with equal numbers of patients treated at each site. All patients receive CaPVax injections and act as their own controls. The treatment plan is presented in Section 5.0. Safety Monitoring A serious adverse event (AE) has been defined on page 19. Consider the patients treated at one of the dose levels (DLs). Denote the probability of an adverse event (AE) at this DL by (theta). The maximum acceptable probability of an AE in a population of patients treated at any DL is .05. We assume that, a priori, (theta) follows a beta distribution with parameters (.10,1.9), which in particular has mean .05. The early stopping criterion is that the DL will be terminated if at any point in the trial Pr[(theta) > .05, data] > .90. Applying this criterion in sequence will terminate that DL if [# patients with an AE ]/ [# patients evaluated] is > or = 2/10, 3/22, 4/35, or 5/50. To apply this rule, note that the boundary "2/10" means that the DL will be discontinued if 2 AEs are observed at any point among the first 10 patients treated at that DL and evaluated, hence 2/2, 2/3, ..., up to 2/10 will cause the DL to be terminated. Similarly, for example, if there are 1/10 and then 2/11 AEs, so that the trial continues to treat patients at that DL at that point, but subsequently one more AE is observed in any patient thereafter up to the 22nd patient evaluated, then that DL is stopped. These rules pertain to all patients evaluated at that DL, including patients in the dose escalation stage. Thus, for example, a DL will be terminated if 2 patients among the first 3 or 6 treated in the dose escalation stage have an AE. 100 For a single dose level with up to 20 patients, this rule has the following operating characteristics: Sample Size 25th, 50th, 75th True Prob[AE] Prob[Early Termination] Percentiles ------------- ----------------------- ---------------------------- .01 .005 20 20 20 .05 .11 20 20 20 .10 .37 10 20 20 .20 .80 5 9 18 .25 .91 4 7 10 Although at most 20 patients will be treated at each dose level if none of the three DLs are terminated early, in the case that a DL is terminated early the remaining patients among the 60 in the trial will be randomized to the remaining dose levels. In this case, more than 20 patients may be treated on each of the remaining DLs. This is a simple "play the winners" strategy. It has the advantage that it is ethically desirable for the patients, since they are less likely to be treated at unsafe DLs, and it is s...

Statistical Considerations. Describe the statistical analyses that support the study design. As this is a pilot evaluation of the acceptability and feasibility of providing CBT4CBT in a Black church setting, data analyses will focus on determining whether the results warrant further adaptation of the existing CBT4CBT program. Criteria for this will include (1) measuring acceptability of treatment by giving each participant a post-intervention satisfaction survey as well as a qualitative exit interview, to fully assesses satisfaction with the intervention, perception of outcome, attitudes about spiritual practices accompanying CBT modules, and whether the participant would recommend this program to a friend. (2) Feasibility will be measured by at least 2/3 of participants (N=27) completing the CBT4CBT intervention. Secondary analyses will include significant reductions in drug use, as measured by mean change scores in the severity and quantity of substance use, and functioning over the course of treatment intervention. The proposed sample size (n=40) is adequate to detect this effect. SECTION VI: RESEARCH INVOLVING DRUGS, BIOLOGICS, PLACEBOS AND DEVICES N/A SECTION VII: HUMAN SUBJECTS